{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:17Z","timestamp":1786982117709,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,4,22]],"date-time":"2012-04-22T00:00:00Z","timestamp":1335052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11886-012-0270-1","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T22:04:23Z","timestamp":1334959463000},"page":"450-456","source":"Crossref","is-referenced-by-count":4,"title":["New Anticoagulants in Ischemic Heart Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Lawrence","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,22]]},"reference":[{"issue":"7","key":"270_CR1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"7","key":"270_CR2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"JL Anderson","year":"2007","unstructured":"Anderson JL, Adams CD, Antman EM, et al. ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1\u2013157.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"270_CR3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jacc.2007.10.001","volume":"51","author":"EM Antman","year":"2008","unstructured":"Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(2):210\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"270_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241\u201350.","journal-title":"Ann Intern Med"},{"issue":"5","key":"270_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519\u201326.","journal-title":"Eur Heart J"},{"issue":"21","key":"270_CR6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","volume":"282","author":"SS Anand","year":"1999","unstructured":"Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282(21):2058\u201367.","journal-title":"JAMA"},{"issue":"5","key":"270_CR7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","volume":"4","author":"DP Faxon","year":"2011","unstructured":"Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4(5):522\u201334.","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"270_CR8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11886-011-0192-3","volume":"13","author":"U Baber","year":"2011","unstructured":"Baber U, Kovacic J, Kini AS, et al. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep. 2011;13(4):312\u20139.","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"270_CR9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382.","journal-title":"Circulation"},{"issue":"12","key":"270_CR10","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","volume":"30","author":"R Mehran","year":"2009","unstructured":"Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30(12):1457\u201366.","journal-title":"Eur Heart J"},{"key":"270_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","volume":"62","author":"BI Eriksson","year":"2011","unstructured":"Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41\u201357.","journal-title":"Annu Rev Med"},{"issue":"2","key":"270_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1592\/phco.29.2.167","volume":"29","author":"PJ Abrams","year":"2009","unstructured":"Abrams PJ, Emerson CR. Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy. 2009;29(2):167\u201381.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"270_CR13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","volume":"1","author":"KG Mann","year":"2003","unstructured":"Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504\u201314.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"270_CR14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"E Perzborn","year":"2005","unstructured":"Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2013an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514\u201321.","journal-title":"J Thromb Haemost"},{"issue":"9683","key":"270_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"issue":"1","key":"270_CR16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"\u2022 Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319. Landmark study showing benefit of adding factor Xa inhibitor rivaroxaban to standard dual antiplatelet therapy with aspirin and clopidogrel, at the expense of major bleeding but not fatal bleeding. Lower-dose regimen also revealed mortality benefit..","journal-title":"N Engl J Med"},{"issue":"17","key":"270_CR17","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"6","key":"270_CR18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","volume":"27","author":"AG Turpie","year":"2007","unstructured":"Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238\u201347.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"270_CR19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","volume":"6","author":"PC Wong","year":"2008","unstructured":"Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820\u20139.","journal-title":"J Thromb Haemost"},{"issue":"22","key":"270_CR20","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877\u201385.","journal-title":"Circulation"},{"issue":"8","key":"270_CR21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"20","key":"270_CR22","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","volume":"32","author":"PG Steg","year":"2011","unstructured":"Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32(20):2541\u201354.","journal-title":"Eur Heart J"},{"issue":"20","key":"270_CR23","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.106.653428","volume":"115","author":"M Cohen","year":"2007","unstructured":"Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation. 2007;115(20):2642\u201351.","journal-title":"Circulation"},{"issue":"9692","key":"270_CR24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","volume":"374","author":"MS Sabatine","year":"2009","unstructured":"\u2022 Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009;374(9692):787\u201395. Otamixaban, an intravenous, direct, selective inhibitor of factor Xa, at intermediate doses in patients presenting with NSTE ACS, may be associated with as much as a 40\u00a0% lower risk of ischemic events and a comparable risk of bleeding compared with UFH+GPI..","journal-title":"Lancet"},{"issue":"6","key":"270_CR25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1160\/TH04-12-0790","volume":"93","author":"RC Becker","year":"2005","unstructured":"Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost. 2005;93(6):1014\u201320.","journal-title":"Thromb Haemost"},{"issue":"3","key":"270_CR26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1160\/TH09-10-0716","volume":"103","author":"RC Becker","year":"2010","unstructured":"Becker RC, Povsic T, Cohen MG, et al. Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost. 2010;103(3):586\u201395.","journal-title":"Thromb Haemost"},{"issue":"23","key":"270_CR27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","volume":"114","author":"CK Dyke","year":"2006","unstructured":"Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006;114(23):2490\u20137.","journal-title":"Circulation"},{"key":"270_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Povsic TJ, Cohen MG, Mehran R et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. Am Heart J. 2011;161(2):261\u20138. e1-2. REG1, an anticoagulation system consisting of a therapeutic RNA aptamer, pegnivacogin, which is a specific factor IXa inhibitor, and its regulator anivamersen, demonstrated numerically lower rates of ischemic events in patients with ACS undergoing PCI. Higher reversal also corresponded to better safety with less bleeding events.","DOI":"10.1016\/j.ahj.2010.10.022"},{"issue":"19","key":"270_CR29","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1093\/eurheartj\/ehr179","volume":"32","author":"TJ Povsic","year":"2011","unstructured":"Povsic TJ, Wargin WA, Alexander JH, et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J. 2011;32(19):2412\u20139.","journal-title":"Eur Heart J"},{"issue":"6","key":"270_CR30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00129784-200505060-00007","volume":"5","author":"SR Steinhubl","year":"2005","unstructured":"Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005;5(6):399\u2013408.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"270_CR31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.31.3.294","volume":"31","author":"UG Eriksson","year":"2003","unstructured":"Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003;31(3):294\u2013305.","journal-title":"Drug Metab Dispos"},{"issue":"9386","key":"270_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362(9386):789\u201397.","journal-title":"Lancet"},{"issue":"3","key":"270_CR33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.thromres.2008.02.017","volume":"123","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123(3):488\u201397.","journal-title":"Thromb Res"},{"issue":"12","key":"270_CR34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"3","key":"270_CR35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"J Stangier","year":"2007","unstructured":"Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292\u2013303.","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"270_CR36","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781\u20139.","journal-title":"Eur Heart J"},{"issue":"20","key":"270_CR37","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"11","key":"270_CR38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-012-0270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-012-0270-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-012-0270-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:46:18Z","timestamp":1561639578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-012-0270-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,22]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s11886-012-0270-1","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,22]]}}}